Relent

Quick links to important sections

Relent

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Relent

Quick Facts

Property Description
Active ingredients Ambroxol Hydrochloride, Cetirizine Hydrochloride
Form Oral liquid suspension (syrup), Tablets
Pharmacological class Mucolytic agent, H₁-receptor antagonist
General purpose Concurrently manages thick secretions and allergic responses
Origin Synthetic drug

Relent: A Fixed-Dose Combination (FDC) Medication

Relent is defined as a synthetic drug and a fixed-dose combination (FDC) pharmaceutical preparation that delivers two distinct therapeutic actions in a single unit. It incorporates two core Active Pharmaceutical Ingredients (APIs): Ambroxol Hydrochloride and Cetirizine Hydrochloride. This specific FDC design is clinically recognized for simplifying the approach to respiratory symptoms by ensuring the simultaneous delivery of both compounds, contrasting with the administration of two separate medications.

Dual Pharmacological Classification and Composition

Relent belongs to a combined pharmacological class, functioning as both a secretolytic compound and a second-generation antihistamine. The presence of Ambroxol designates its mucolytic agent action, primarily aimed at reducing the viscosity of thick respiratory secretions. Ambroxol is utilized for its secretolytic efficacy in various respiratory conditions.

The second component, Cetirizine, is classified as a selective H₁-receptor antagonist, or anti-allergic agent. Its role is to mitigate allergic responses. Cetirizine provides reliable and persistent anti-allergic action. Relent is available for oral administration as both a liquid suspension and a tablet.

General Therapeutic Purpose

The general purpose of Relent is to provide integrated management for respiratory discomfort involving both excessive, thick secretions and associated allergic manifestations. The combination is engineered to deliver a cohesive therapeutic strategy that addresses these two frequent co-factors. This approach ensures that the mucolytic agent facilitates mucus clearance while the anti-allergic agent concurrently acts to mitigate symptoms stemming from inflammation, ultimately supporting improved overall airway clearance.

What side effects are possible with Relent?

Possible Side Effects and Safety Information

The official safety profile for the fixed-dose combination Relent (Ambroxol/Cetirizine) is structured according to regulatory classifications, detailing adverse reactions by frequency and physiological system affected.

Frequency and System-Organ Classes

The most frequent adverse reactions are generally classified as Common and typically involve the central nervous system and local effects. These can include somnolence (drowsiness), headache, fatigue, and dry mouth [Source: FDA DailyMed Label for Cetirizine]. Less common reactions, classified as Uncommon or Rare, involve gastrointestinal disturbances such as nausea, vomiting, abdominal pain, and diarrhea [Source: TGA Public Summary Documents].

Side effects are primarily grouped into the following categories according to regulatory System-Organ Classes (SOC):

  • Nervous System Disorders (e.g., somnolence, headache)
  • Gastrointestinal Disorders (e.g., nausea, dry mouth)
  • Immune System and Skin Disorders

Serious Adverse Reactions and Safety Constraints

The regulatory profile documents the potential for rare but serious adverse reactions. These include severe, systemic immune responses such as Anaphylactic Shock and severe skin reactions known as Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) [Source: EMA Ambroxol/Bromhexine referral].

Official labeling defines specific safety constraints for certain populations. The Cetirizine component requires that dose adjustment be considered in patients with moderate to severe renal impairment due to reduced drug clearance [Source: Health Canada Product Monograph]. Additionally, somnolence is noted as an effect that may be more noticeable at the initiation of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for the components of Relent, detailing expected clinical signs and mandatory emergency actions. Overdose manifestations documented for the active ingredients typically include Central Nervous System effects such as drowsiness, somnolence, confusion, headache, and restlessness. Anticholinergic signs like tachycardia (fast heart rate) and urinary retention are also reported in regulatory texts.

Severe, high-dose ingestions carry a documented risk of serious outcomes, including convulsions (seizures), cardiac arrhythmia, and coma. In the pediatric population, initial symptoms of overdose may present as restlessness prior to sedation. Treatment is classified as strictly symptomatic and supportive, as official regulatory information confirms that no specific antidote is known for either component.

Mandatory Emergency Actions

Situation Regulator-Mandated Action
Suspected overdose or mild symptoms Seek immediate medical attention or consult a doctor.
Severe symptoms (e.g., seizure, inability to awaken) Call emergency services (e.g., 911) immediately.

Procedural measures such as gastric lavage or the use of activated charcoal may be considered in a medical setting to reduce absorption, based on official prescribing information.

Therapeutic Uses of Relent

What Relent treats: main uses and benefits

Relief for Dual Respiratory and Allergic Discomfort

This medication is generally applied in clinical settings that involve symptoms related to inflammatory or irritative states alongside symptoms related to physical discomfort from thick secretions. It is commonly used across conditions presenting with acute episodes, such as allergic rhinitis, bronchitis, and symptomatic phases of the common cold, particularly when these conditions involve a combination of both mucus build-up and allergic signs. The mucolytic component is commonly used to help with addressing the issue of viscid secretions, which is often needed for improved breathing. This support offers symptomatic relief when symptoms interfere with routine activities.

“The combination of addressing both mucus viscosity and allergic response is relevant in clinical scenarios where symptoms cluster into patterns requiring supportive management.”

Facilitating Airway Clearance and Symptom Management

The medication is used for managing symptom clusters that may become intense or disruptive, especially a productive cough in conditions marked by increased physiological stress. It is applied in addressing symptoms that create noticeable physiological strain by targeting viscid, excessive mucus. This support contributes to improved day-to-day comfort during periods of heightened symptoms and assists with maintaining functional stability. The medication is also relevant in contexts involving heightened systemic burden from allergies, helping manage persistent runny nose, nasal congestion, and watery eyes related to hay fever.

Quick Fact: Relief for Dual Symptoms Description
Mucus Domain Used for managing viscid, thick, or excessive secretions and productive cough.
Allergy Domain Applied for common allergic manifestations, including rhinitis, sneezing, and watery eyes.
Patient Benefit Supports easing the overall symptom load, contributing to improved comfort.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

The eligibility for the fixed-dose combination Relent (Ambroxol Hydrochloride and Cetirizine Hydrochloride) is governed by formal restrictions established in regulatory prescribing information, defining who must not use the medicine and under what conditions its use is limited.

Absolute Contraindications (Must Not Use):

Population / Condition Restriction Status
Hypersensitivity Contraindicated (to Ambroxol, Cetirizine, or any ingredient)
Severe Renal Impairment Contraindicated (creatinine clearance typically < 10 mL/min)
Severe Gastric/Ulcer Problems Contraindicated (active or history of gastric ulceration)
Severe Skin Disorders Contraindicated (e.g., known history of Stevens-Johnson syndrome)

Age and Physiological Status Restrictions:

  • Pediatric Use: The use of Relent is not generally recommended in children under 2 years of age, as safety and efficacy are not established in this population. Use for children under 6 years may be restricted to specific formulations, such as syrup.
  • Older Adults: Use requires caution, and dose adjustment may be necessary due to the potential for underlying kidney function impairment.
  • Pregnancy and Breastfeeding: Use is officially not recommended during both pregnancy and lactation, as components of the medicine pass into breast milk and may cause potential harm.

Conditional Use (Requires Caution):

  • Patients with non-severe renal impairment or hepatic impairment require medical consultation and potential dosage modification.
  • Caution is advised for patients with a history of epilepsy or a predisposition for urinary retention.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Relent, a fixed-dose combination, has an official interaction profile based on the documented effects of its active components, Ambroxol (mucolytic) and Cetirizine (antihistamine). These interactions are classified by regulatory authorities based on pharmacodynamic conflicts and pharmacokinetic changes.

Documented Interaction Patterns

Interaction Type Interacting Substance/Class Official Regulatory Statement
Pharmacodynamic Alcohol and CNS Depressants Co-administration with Cetirizine may cause an additive reduction in alertness and impairment of CNS performance.
Pharmacodynamic Antitussives (Cough Suppressants) Not generally recommended with Ambroxol due to the formal risk of inhibiting the cough reflex, leading to the accumulation of viscid secretions.
Pharmacokinetic Theophylline (400 mg dose) Formally documented to decrease the clearance of Cetirizine, which increases systemic drug exposure.
Pharmacokinetic Specific Antibiotics Ambroxol co-administration increases the concentration of certain antibiotics (e.g., Amoxicillin, Erythromycin) in bronchopulmonary secretions.

Additional Constraints and Considerations

The regulatory profile documents that food consumption decreases the rate of absorption of the Cetirizine component, although the total amount absorbed is not reduced. Furthermore, the official labeling notes that in cases of severe hepatic or renal impairment, the clearance of both Ambroxol and Cetirizine is reduced, resulting in increased systemic exposure risk in these populations.

Mechanism of Action

How Relent Works

️ Coordinated Action on Secretion Viscosity and Airway Patency

This fixed-dose combination incorporates agents that act upon specific systems within the respiratory tract. The first component promotes the synthesis and release of pulmonary surfactant and acts within cells that contribute to the depolymerization of mucopolysaccharide fibers. This action results in reduced viscosity and adhesiveness of secretions, which enhances the efficiency of the mucociliary clearance mechanism.

Selective Histamine Blockade and Anti-Inflammatory Modulation

The second component works through competitive antagonism at the peripheral Histamine H1 receptors, inhibiting the ability of histamine to activate the allergic signaling cascade. By blocking this early step, the mechanism results in the modulation of vascular dynamics, which reduces the degree of vascular permeability and fluid extravasation into the respiratory mucosa. This action also extends to modulating the late-phase response by inhibiting the recruitment of inflammatory cells.

Local Inhibition of Sensory Signals

An additional physiological effect is provided by the mucolytic agent's ability to inhibit Voltage-Gated Na^+ Channels on peripheral sensory nerves. This targeted blockade stabilizes the nerve cell membrane, which results in a reduction of afferent sensory signal transmission. These three distinct mechanistic domains work concurrently to modulate secretion properties, inflammatory responses, and sensory input within the respiratory system.

Dosage and Administration Information

How Relent is Used in Clinical Practice

Relent, a fixed-dose combination medication, is intended for oral administration only and is available in both tablet and liquid suspension forms. Standard usage instructions outline how the medicine is taken to ensure proper administration and reduce the risk of gastrointestinal irritation from the mucolytic component.

Administration and Timing

Standard dosing for adults and adolescents 12 years and older typically involves a total daily dose of the Cetirizine component that does not exceed 10 mg. Due to the fixed combination and the presence of Ambroxol, the dosing frequency is commonly structured as once daily or twice daily as prescribed. It is generally instructed that the medication should be taken after meals (postprandially).

For the liquid suspension, the dose must be accurately determined using the calibrated measuring device supplied with the product. Tablets should be swallowed whole with a glass of water and must not be crushed or chewed.

Duration and Special Population Rules

Relent is primarily used for short-term symptomatic management of acute episodes. Use extending beyond this acute phase, particularly for chronic conditions, requires medical supervision. Dose modification is a requirement for certain patient populations:

  • Renal Impairment: Patients with moderate to severe kidney dysfunction require a dose reduction or an extension of the dosing interval, for example, 5 mg of the Cetirizine component every two days.

If a dose is missed, it is standard procedural instruction to skip the missed dose and resume the regular schedule; a double dose should not be taken to compensate.

Recent Clinical Evidence

Research evidence / Overview of studies for Relent

Evidence for the Combination's Use in Productive Cough and Allergic Symptoms

Research examining the fixed-dose combination (FDC) of Ambroxol and Cetirizine has primarily focused on conditions characterized by fluctuating or episodic manifestations, particularly where thick, difficult-to-clear mucus is combined with outcomes linked to inflammatory or irritative states (e.g., runny nose and sneezing). Studies conducted during periods of increased symptom activity include randomized, prospective, multi-center trials. These trials typically compared the FDC to the mucolytic component (Ambroxol) administered alone.

The research explored how symptoms change over time in the observed populations, with a focus on patients with productive cough and associated nasal symptoms. Studies reported measurements where a difference in the observed patterns of the Total Symptom Score (TSS) and Total Nasal Symptom Score (TNSS) was noted when the anti-allergic component was included, particularly when outcomes were measured at short, predefined time intervals, such as day 3 and day 7.

Evidence from Trials on the Mucolytic Component (Ambroxol)

The mucolytic agent, Ambroxol, has been the subject of research for many years, with studies evaluating its use in various conditions involving viscid secretions and impaired mucus transport. This evidence base consists of a broad range of Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. Research monitored outcomes reflecting daily functioning and observed patterns related to the frequency of acute exacerbations and measurements of sputum viscosity. Studies contribute to the broader evidence landscape regarding the effects monitored in trials of the Ambroxol component.

Follow-Up Duration and the Long-Term Evidence Landscape

The follow-up durations for the specific FDC trials exploring productive cough and associated allergic manifestations have been limited, typically spanning short-term intervals of one week or less. Research focusing on episodes where symptoms become more noticeable generally observes responses over defined, short time intervals consistent with short-term therapeutic use.

There is limited information for long-term outcomes and the continuous management of chronic conditions specifically using the Ambroxol-Cetirizine FDC. Any evidence regarding the persistence of effects or use in long-term prophylactic settings derives primarily from the research profiles of the individual components.

Frequently Asked Questions (FAQ)

Common questions about Relent (FAQ)


Q: Can Relent be taken with common over-the-counter cold medicines?

Regulatory documents advise caution when combining this medicine with other Central Nervous System (CNS) depressants, as this may increase the effect of drowsiness or reduced alertness.

The product is formally documented as not generally recommended for co-administration with antitussives (cough suppressants) because of a documented risk of potentially inhibiting the cough reflex and causing secretions to accumulate.


Q: Does Relent affect the ability to drive or operate machinery?

Official regulatory documents note that common side effects, such as drowsiness (somnolence) and fatigue, may occur.

Due caution is advised regarding any activities that require mental alertness, including driving a car or operating potentially dangerous machinery.


Q: What conditions make a person ineligible to use Relent?

Absolute restrictions, known as contraindications, include known hypersensitivity to any ingredient, severe renal (kidney) impairment, and active or a history of severe gastric ulceration.

Official eligibility restrictions note that caution is advised for patients with a history of epilepsy or non-severe kidney or liver impairment.


Q: Can Relent be taken with blood pressure medication?

The official regulatory profile does not formally document an interaction between this medicine and blood pressure medications (antihypertensives).

The document only lists specific pharmacokinetic and pharmacodynamic interactions with agents like alcohol, antitussives, and Theophylline.


Q: Can men and women take the same dose of Relent?

Official prescribing information describes a standardized dosing structure for adults and adolescents that does not differentiate based on sex.

The only criteria that typically necessitate dose modification relate to underlying health issues, such as the degree of renal (kidney) impairment.


Q: Does taking Relent long-term cause any different side effects?

The research conducted on the specific combination is primarily limited to short-term use, typically for acute episodes lasting one week or less.

However, regulatory authorities have noted that stopping the antihistamine component after use extending over many months or years may rarely result in an onset of intense itching (pruritus).


Q: How long does it typically take to feel the effects of Relent?

Official pharmacokinetic information indicates that the antihistamine component typically begins to exert its effects relatively quickly, often starting within 20 to 60 minutes after the medicine is taken by mouth.


Q: Can Relent be taken by children?

The official guidance for this fixed-dose combination generally restricts use to individuals 12 years and older.

Specific formulations may be approved for use in children over 6 years of age, but official restrictions describe that use is not generally recommended for children under 2 years old, as safety and efficacy are not established in that age group.


Q: How long does Relent stay in your system after stopping it?

The time a medicine stays in the body is often measured by its elimination half-life.

For the antihistamine component, this half-life is described in regulatory sources as approximately 8.3 hours in healthy adult volunteers.


Q: Is Relent addictive?

The active ingredients in Relent are not formally classified as controlled substances in major regulatory schedules.

Official documents do not formally indicate a potential for physical dependence or abuse for this medicine.


Q: Is Relent a controlled substance?

Relent is not listed on the Schedules of Controlled Substances by regulatory bodies, such as those in the United States or other major international jurisdictions.


Q: What happens if someone misses a dose of Relent?

The official regulatory procedure for managing a missed dose is to skip that dose entirely.

Individuals are instructed to take the next scheduled dose at the usual time and are explicitly advised against taking a double dose to make up for the one that was missed.


Q: How long can Relent be safely used for?

The product is primarily intended for short-term symptomatic management of acute episodes, consistent with its approval for temporary use.

Official information describes that use extending beyond the acute phase requires medical supervision.


Q: Can Relent interfere with blood tests?

While the medicine does not typically interfere with standard blood tests, official guidelines advise caution regarding diagnostic procedures.

Specifically, the antihistamine component can interfere with the results of allergy skin tests, and its discontinuation is advised before these procedures.


Q: Can Relent be used for other purposes besides what it is approved for?

The general purpose of Relent is officially defined as providing integrated management for respiratory discomfort involving excessive, thick secretions and associated allergic manifestations.

Regulatory documents do not provide information or guidance on the use of this medicine for any other purposes.


Q: Why does Relent sometimes get prescribed with a second medicine?

One documented reason is related to official interaction patterns with antibiotics.

Regulatory information documents that the mucolytic component can increase the concentration of certain antibiotics in bronchopulmonary secretions, which may be beneficial in some co-prescribing strategies.


Q: Can Relent be stopped suddenly, or does it need to be tapered off?

Official safety information does not generally mandate a dose taper when stopping the medicine.

However, authorities have noted that if intense itching occurs following long-term discontinuation, symptoms may improve upon the reintroduction and gradual reduction of the medication.


Q: Is it safe to drink alcohol in moderation while on Relent?

Official regulatory warnings document that taking this medicine concurrently with alcohol has the potential to cause an additive reduction in alertness.

This combination may also lead to an increased impairment of central nervous system performance.


Q: Does Relent cause weight gain or weight loss?

Weight gain or weight loss are not listed among the most frequent or common adverse reactions in the official safety profile.

However, research into the antihistamine component has noted an association between its use over extended periods and potential changes in appetite and body weight.


Q: Are there any known severe drug interactions with narcotics or opioids and Relent?

The official label issues a warning regarding co-administration with Central Nervous System (CNS) depressants, a category that includes narcotics and opioids.

Combining these substances may lead to an additive reduction in alertness and impairment of CNS performance.


Q: Does Relent have a Black Box Warning in the US?

Based on current regulatory information from the United States, the official labeling for Relent does not carry a Black Box Warning.

This warning is the FDA’s most stringent advisory regarding serious safety risks associated with a medication.

How should Relent be stored and disposed of?

How to Store and Dispose of Relent

Official regulatory guidelines define specific conditions to maintain the integrity of Relent (Ambroxol Hydrochloride and Cetirizine Hydrochloride) formulations.

Storage Requirements

Formulation Required Storage Condition Environmental Restriction
Tablets Store below 25°C Protect from moisture
Oral Liquid (Syrup) Store below 30°C Do not freeze; Keep tightly closed

The syrup must be kept in the original, tightly closed container. A mandatory post-opening stability period requires that any unused oral liquid must be discarded four weeks after the bottle has been opened. All formulations must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired medicine must be disposed of according to local regulatory requirements. Disposal via wastewater or household waste is prohibited, aligning with environmental protection guidelines. Patients should utilize a medicine take-back program when available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Relent found in:

A-Z Index: